A Comprehensive Review of Hypertension in Pregnancy

Hypertension is the most common medical disorder encountered during pregnancy. Hypertensive disorders are one of the major causes of pregnancy-related maternal deaths in the United States. We will present a comprehensive update of the literature pertinent to hypertension in pregnancy. The paper begins by defining and classifying hypertensive disorders in pregnancy. The normal vascular and renal physiological changes which occur during pregnancy are detailed. We will summarize the intriguing aspects of pathophysiology of preeclampsia, emphasizing on recent advances in this field. The existing diagnostic tools and the tests which have been proposed for screening preeclampsia are comprehensively described. We also highlight the short- and long-term implications of preeclampsia. Finally, we review the current management guidelines, goals of treatment and describe the potential risks and benefits associated with various antihypertensive drug classes. Preeclampsia still remains an enigma, and the present management focuses on monitoring and treatment of its manifestations. We are hopeful that this in depth critique will stimulate the blossoming research in the field and assist practitioners to identify women at risk and more effectively treat affected individuals.

[1]  I. Sargent,et al.  Immunology of Normal Pregnancy and Preeclampsia , 2009 .

[2]  L. Magee,et al.  Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. , 2014, Pregnancy hypertension.

[3]  C. Homer,et al.  Predicting Transformation from Gestational Hypertension to Preeclampsia in Clinical Practice: A Possible Role for 24 Hour Ambulatory Blood Pressure Monitoring , 2007, Hypertension in pregnancy.

[4]  A. Morrison,et al.  Allelic variations in angiogenic pathway genes are associated with preeclampsia. , 2009, American journal of obstetrics and gynecology.

[5]  A. Korda,et al.  Clonidine hydrochloride‐A safe and effective antihypertensive agent in pregnancy , 1985, Obstetrics and gynecology.

[6]  T. Leivestad,et al.  Preeclampsia and the risk of end-stage renal disease. , 2008, The New England journal of medicine.

[7]  S. Vreeburg,et al.  Hypertension during pregnancy in South Australia, Part 2: Risk factors for adverse maternal and/or perinatal outcome – results of multivariable analysis , 2004, The Australian & New Zealand journal of obstetrics & gynaecology.

[8]  M. Brown,et al.  Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. , 2002, American journal of obstetrics and gynecology.

[9]  A. Decherney,et al.  Relaxin , 1960, Nature.

[10]  I. Greer,et al.  Manifestations of chronic disease during pregnancy. , 2005, JAMA.

[11]  H. Stenlund,et al.  Long-term Impact of Reproductive Factors on the Risk of Cervical, Endometrial, Ovarian and Breast Cancer , 2001, Acta oncologica.

[12]  G. Koren,et al.  The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. , 1996, American journal of obstetrics and gynecology.

[13]  K. Newton,et al.  Preeclampsia and Risk of Developing Subsequent Diabetes , 2009, Hypertension in pregnancy.

[14]  L. Magee,et al.  Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis , 2003, BMJ : British Medical Journal.

[15]  B. Sibai,et al.  Chronic hypertension in pregnancy. , 1991, Obstetrics and gynecology clinics of North America.

[16]  B. Sibai,et al.  A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term , 1987, Obstetrics and gynecology.

[17]  P. McKenzie,et al.  Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. , 2007, Kidney international.

[18]  Sanjeev G Shroff,et al.  Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. , 2006, Endocrinology.

[19]  E. Lieberman,et al.  Use of a random urinary protein-to-creatinine ratio for the diagnosis of significant proteinuria during pregnancy. , 2001, American journal of obstetrics and gynecology.

[20]  R. Romero,et al.  Tests to Predict Preeclampsia , 2009 .

[21]  L. Beilin,et al.  TREATMENT OF HYPERTENSION IN PREGNANCY WITH METHYLDOPA: BLOOD PRESSURE CONTROL AND SIDE EFFECTS , 1977, British journal of obstetrics and gynaecology.

[22]  S. Montán,et al.  Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. , 1993, American journal of obstetrics and gynecology.

[23]  R K Craig,et al.  Methods in molecular medicine. , 1987, British medical journal.

[24]  Christopher P Price,et al.  Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. , 2005, Clinical chemistry.

[25]  Joshua R. Smith,et al.  Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[26]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.

[27]  G. H. Lambert,et al.  Transfer of drugs and other chemicals into human milk. , 2001, Pediatrics.

[28]  A. Hingorani,et al.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[29]  S. Y. Park,et al.  Effective Prediction of Preeclampsia by a Combined Ratio of Angiogenesis-Related Factors , 2008, Obstetrics and gynecology.

[30]  A. Coomarasamy,et al.  Accuracy of serum uric acid in predicting complications of pre‐eclampsia: a systematic review , 2006, BJOG : an international journal of obstetrics and gynaecology.

[31]  J. Creeden,et al.  Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective , 2010, Journal of medical economics.

[32]  J. Laragh,et al.  Hypocalciuria in preeclampsia. , 1987, The New England journal of medicine.

[33]  A. Makris,et al.  Postpartum hypertension and nonsteroidal analgesia. , 2004, American journal of obstetrics and gynecology.

[34]  Donna D. Johnson,et al.  Soluble endoglin as a second-trimester marker for preeclampsia. , 2007, American journal of obstetrics and gynecology.

[35]  Robert N. Taylor,et al.  Endothelial Cell Dysfunction and Oxidative Stress , 2009 .

[36]  S. Crawford,et al.  Soluble Endoglin for the Prediction of Preeclampsia in a High Risk Cohort , 2010, Hypertension in pregnancy.

[37]  A. Odutayo,et al.  The kidney in normal pregnancy and preeclampsia. , 2011, Seminars in nephrology.

[38]  J. Granger,et al.  Hypertension Produced by Placental Ischemia in Pregnant Rats Is Associated With Increased Soluble Endoglin Expression , 2009, Hypertension.

[39]  J. Davison,et al.  The renal response to preeclampsia. , 2004, Seminars in nephrology.

[40]  T. Kiran,et al.  Is the urine spot protein/creatinine ratio a valid diagnostic test for pre-eclampsia? , 2011, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[41]  J. Roberts,et al.  Endothelial Dysfunction in Preeclampsia , 1998, Seminars in reproductive endocrinology.

[42]  K. Zerres,et al.  Genes and the preeclampsia syndrome , 2008, Journal of perinatal medicine.

[43]  R. T. Lie,et al.  Fetal and maternal contributions to risk of pre-eclampsia: population based study , 1998, BMJ.

[44]  J. D. Neill,et al.  The Physiology of reproduction , 1988 .

[45]  Robert N. Taylor,et al.  Angiogenesis and Preeclampsia , 2012, Chesley's Hypertensive Disorders in Pregnancy.

[46]  T. Shike,et al.  Animal models. , 2001, Contributions to nephrology.

[47]  Santosh A. Khedkar,et al.  Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia , 2011, Circulation.

[48]  A. Sedman,et al.  Angiotensin-converting enzyme inhibitor fetopathy. , 1993, Journal of the American Society of Nephrology : JASN.

[49]  G. Dekker,et al.  Prediction of pregnancy‐induced hypertensive disorders by angiotensin II sensitivity and supine pressor test , 1990, British journal of obstetrics and gynaecology.

[50]  S. Karumanchi,et al.  Preeclampsia and the Anti-Angiogenic State. , 2011, Pregnancy hypertension.

[51]  L. Vatten,et al.  Pre-eclampsia in pregnancy and subsequent risk for breast cancer , 2002, British Journal of Cancer.

[52]  A. Benigni,et al.  Mapping the Theories of Preeclampsia and the Role of Angiogenic Factors: A Systematic Review , 2007, Obstetrics and gynecology.

[53]  E. Begg,et al.  Concentrations of beta-blocking drugs in human milk. , 1990, The Journal of pediatrics.

[54]  D. Arduini,et al.  Effects of nifedipine on umbilical artery velocity waveforms in healthy human fetuses. , 1987, Gynecologic and obstetric investigation.

[55]  D. Lewis,et al.  Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. , 2008, The Journal of clinical endocrinology and metabolism.

[56]  W. White Management of hypertension during lactation. , 1984, Hypertension.

[57]  S. Chand,et al.  A clinical test useful for predicting the development of acute hypertension in pregnancy. , 1974, American journal of obstetrics and gynecology.

[58]  E. Burgess,et al.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[59]  T. Musci,et al.  Preeclampsia: an endothelial cell disorder. , 1989, American journal of obstetrics and gynecology.

[60]  R. Ehrenkranz,et al.  Nifedipine transfer into human milk. , 1989, The Journal of pediatrics.

[61]  J. Granger,et al.  Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. , 2006, Methods in molecular medicine.

[62]  B. Mol,et al.  Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[63]  Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. , 2000, American journal of obstetrics and gynecology.

[64]  D. Henderson-smart,et al.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. , 2014, The Cochrane database of systematic reviews.

[65]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[66]  L. Magee Drugs in pregnancy. Antihypertensives. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[67]  J. Kooner,et al.  Association of maternal endothelial dysfunction with preeclampsia. , 2001, JAMA.

[68]  M. Hadders‐Algra,et al.  Is clonidine a behavioural teratogen in the human? , 1986, Early human development.

[69]  S. Blackwell,et al.  Angiotensin Receptor Agonistic Autoantibody Is Highly Prevalent in Preeclampsia: Correlation With Disease Severity , 2010, Hypertension.

[70]  G. Lip,et al.  Effect of atenolol on birth weight. , 1997, The American journal of cardiology.

[71]  W. Raab,et al.  Vascular reactivity and electrolytes in normal and toxemic pregnancy; pathogenic considerations and a diagnostic pre-toxemia test. , 1956, The Journal of clinical endocrinology and metabolism.

[72]  E. M. Symonds,et al.  The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. , 1989, British journal of obstetrics and gynaecology.

[73]  C. Berg,et al.  Pregnancy‐Related Mortality From Preeclampsia and Eclampsia , 2001, Obstetrics and gynecology.

[74]  V. Apgar,et al.  DRUGS IN PREGNANCY. , 1965, JAMA.

[75]  N. Wasserstrum Nitroprusside in Preeclampsia Circulatory Distress and Paradoxical Bradycardia , 1991, Hypertension.

[76]  R. Kauffman,et al.  Transfer of drugs and other chemicals into human milk. , 1989, Pediatrics.

[77]  S. Lindow,et al.  The effect of nifedipine on fetal umbilical artery Doppler waveforms in pregnancies complicated by hypertension. , 1991, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[78]  B. Sibai,et al.  Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. , 1991, American journal of obstetrics and gynecology.

[79]  R. Carr-Hill,et al.  Pre‐eclampsia in second pregnancy , 1985 .

[80]  G. A. D. Gynaecologist Prediction of pregnancy-induced hypertensive disorders by angiotensin II sensitivity and supine pressor test , 2005 .

[81]  E. Seely,et al.  Clinical practice. Chronic hypertension in pregnancy. , 2011, The New England journal of medicine.

[82]  S. Lindow,et al.  The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy , 1988, British journal of obstetrics and gynaecology.

[83]  Harpar S. Buttar An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development , 1997, Molecular and Cellular Biochemistry.

[84]  G. Massicotte,et al.  Chronic decrease of blood pressure by rat relaxin in spontaneously hypertensive rats. , 1985, Life sciences.

[85]  F. Hisaw Experimental relaxation of the pubic ligament of the guinea pig. , 1926 .

[86]  L. Butters,et al.  First year of life after the use of atenolol in pregnancy associated hypertension. , 1984, Archives of disease in childhood.

[87]  Lewis H Kuller,et al.  Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. , 2004, American journal of physiology. Heart and circulatory physiology.

[88]  G. Stoddard,et al.  Preeclampsia and subsequent risk of cancer in Utah. , 2006, American journal of obstetrics and gynecology.

[89]  R. Jeremy,et al.  Structural and functional changes in left ventricle during normotensive and preeclamptic pregnancy. , 2002, American journal of physiology. Heart and circulatory physiology.

[90]  J. Davison,et al.  Overview: Kidney Function in Pregnant Women , 1987 .

[91]  B. Sibai,et al.  Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. , 2010, American journal of obstetrics and gynecology.

[92]  M. Varner,et al.  Paternal and maternal components of the predisposition to preeclampsia. , 2001, The New England journal of medicine.

[93]  G. Wallukat,et al.  Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. , 1999, The Journal of clinical investigation.

[94]  H. V. van Geijn,et al.  Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[95]  D. James,et al.  Pre‐eclampsia and trisomy 13 , 1992, British journal of obstetrics and gynaecology.

[96]  S. Shroff,et al.  Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. , 2004, Endocrinology.

[97]  P. Siiteri,et al.  Placental characteristics and reduced risk of maternal breast cancer. , 2001, Journal of the National Cancer Institute.

[98]  M. de Swiet,et al.  The management of postpartum hypertension , 2002, BJOG : an international journal of obstetrics and gynaecology.

[99]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[100]  B. Sibai,et al.  Pregnancy Outcomes in Healthy Nulliparas Who Developed Hypertension , 2000, Obstetrics and gynecology.

[101]  A. Pastuszak,et al.  Drugs in pregnancy. , 1998, The New England journal of medicine.

[102]  N. Wessel,et al.  Predictive Value of Maternal Angiogenic Factors in Second Trimester Pregnancies With Abnormal Uterine Perfusion , 2007, Hypertension.

[103]  J. Hall Vascular reactivity and electrolytes in normal and toxemic pregnancy , 1957 .

[104]  B. Sibai,et al.  Magnesium Sulfate in Women With Mild Preeclampsia: A Randomized Controlled Trial , 2003, Obstetrics and gynecology.

[105]  W. Holzgreve,et al.  Reproductive Biology and Endocrinology Open Access Potential Markers of Preeclampsia – a Review , 2022 .

[106]  E. Widerlöv,et al.  Hydralazine-induced neonatal thrombocytopenia. , 1980, The New England journal of medicine.

[107]  V. Garovic The role of angiogenic factors in the prediction and diagnosis of preeclampsia superimposed on chronic hypertension. , 2012, Hypertension.

[108]  K. Khan,et al.  How useful is uterine artery Doppler flow velocimetry in the prediction of pre‐eclampsia, intrauterine growth retardation and perinatal death? An overview , 2000, BJOG : an international journal of obstetrics and gynaecology.

[109]  C. Johnson,et al.  A sister's risk: family history as a predictor of preeclampsia. , 2005, American journal of obstetrics and gynecology.

[110]  M. Rönnback,et al.  Impaired vascular dilatation in women with a history of pre-eclampsia , 2006, Journal of hypertension.

[111]  R. Liston,et al.  Random Protein‐Creatinine Ratio for the Quantitation of Proteinuria in Pregnancy , 1997, Obstetrics and gynecology.

[112]  S. Vreeburg,et al.  Hypertension during pregnancy in South Australia, Part 1: Pregnancy outcomes , 2004, The Australian & New Zealand journal of obstetrics & gynaecology.

[113]  H. Odendaal,et al.  Serotonin Antagonism and Serotonin Antagonists in Pregnancy: Role of Ketanserin , 2000, Obstetrical & gynecological survey.

[114]  A. Hunter,et al.  Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. , 2004, American journal of obstetrics and gynecology.

[115]  M. Bennett,et al.  Phaeochromocytoma in pregnancy. , 1959, Lancet.

[116]  B. Sibai,et al.  Prediction and prevention of recurrent preeclampsia. , 2008, Obstetrics and gynecology.

[117]  R. Kaaja,et al.  Insulin resistance and sympathetic overactivity in women. , 2006, Journal of hypertension.

[118]  L. Impey Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks , 1993, British journal of obstetrics and gynaecology.

[119]  S. Maynard,et al.  Angiogenic factors and preeclampsia. , 2011, Seminars in nephrology.

[120]  K. Conrad Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. , 2011, Seminars in nephrology.

[121]  P. August,et al.  Update on the use of antihypertensive drugs in pregnancy. , 2008, Hypertension.

[122]  Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy , 2008 .

[123]  R. Romero,et al.  Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[124]  S. Hernández-Díaz,et al.  Major congenital malformations after first-trimester exposure to ACE inhibitors. , 2006, The New England journal of medicine.

[125]  K. Khan,et al.  Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[126]  S. Kennedy,et al.  Atenolol in essential hypertension during pregnancy. , 1990, BMJ.

[127]  J. Soustiel,et al.  The effect of isosorbide dinitrate, a donor of nitric oxide, on maternal cerebral blood flow in gestational hypertension and preeclampsia. , 2003, American journal of obstetrics and gynecology.

[128]  S. Chand,et al.  A study of angiotensin II pressor response throughout primigravid pregnancy. , 1973, The Journal of clinical investigation.

[129]  A. Skrondal,et al.  Recurrence risk of preeclampsia in twin and singleton pregnancies , 2004, American journal of medical genetics. Part A.

[130]  G. ter Riet,et al.  Accuracy of serum uric acid determination in predicting pre‐eclampsia: A systematic review , 2006, Acta obstetricia et gynecologica Scandinavica.

[131]  B. Corenblum,et al.  Spironolactone therapy during human pregnancy. , 1995, American journal of obstetrics and gynecology.

[132]  L. Florea,et al.  Novel splice variants of sFlt1 are upregulated in preeclampsia. , 2009, Placenta.

[133]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[134]  B. Sibai,et al.  Mild gestational hypertension remote from term: progression and outcome. , 2001, American journal of obstetrics and gynecology.

[135]  D. Kallogjeri,et al.  Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. , 2008, American journal of obstetrics and gynecology.

[136]  J. Catov,et al.  First trimester uric acid and adverse pregnancy outcomes. , 2011, American journal of hypertension.

[137]  Donna D. Johnson,et al.  Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. , 2006, American journal of obstetrics and gynecology.

[138]  B. Sibai,et al.  Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. , 1986, American journal of obstetrics and gynecology.

[139]  R. Abdul-karim,et al.  Pressor response to angiotonin in pregnant and nonpregnant women. , 1961, American journal of obstetrics and gynecology.

[140]  F. Corrado,et al.  Endoglin, PlGF and sFlt‐1 as markers for predicting pre‐eclampsia , 2008, Acta obstetricia et gynecologica Scandinavica.

[141]  N. Wessel,et al.  Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. , 2008, American journal of obstetrics and gynecology.

[142]  R. Peto,et al.  Overview of randomised trials of diuretics in pregnancy. , 1985, British medical journal.

[143]  B. Sibai,et al.  Eclampsia. VII. Pregnancy outcome after eclampsia and long-term prognosis. , 1992, American journal of obstetrics and gynecology.